Abbott Laboratories (NYSE:ABT) is addressing ongoing headwinds in its Nutrition segment with changes to pricing, promotions, and cost structures, with a shift signaled to begin in the fourth quarter. The company is moving ahead with the pending acquisition of Exact Sciences to expand its presence in cancer diagnostics. Abbott is also rolling out new products in diabetes care and cardiovascular devices, supported by recent regulatory approvals. For investors watching NYSE:ABT, the key story right now is how the business is rebalancing between challenged Nutrition operations and areas such as diabetes care and medical devices. Nutrition has weighed on recent sentiment, so the planned reset in pricing, promotions, and costs is an important development. This comes alongside efforts to keep its device franchises competitive through new product launches.At the same time, the pending Exact Sciences acquisition signals a push into cancer diagnostics, which would add a new vertical to Abbott’s existing portfolio in diagnostics, devices, and nutrition. Together, these moves frame a period of portfolio adjustment that may reshape how the company allocates capital and attention across its major business lines.Stay updated on the most important news stories for Abbott Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.NYSE:ABT Earnings & Revenue Growth as at Jan 2026How Abbott Laboratories stacks up against its biggest competitorsFor you as an investor, the key takeaway is that Abbott is using a tough quarter in Nutrition as a catalyst to rebalance the business mix, while leaning into areas like diabetes care and cardiovascular devices where product launches and regulatory approvals are already in motion. The pending US$21b Exact Sciences deal would further tilt the company toward diagnostics and cancer screening, placing it more squarely alongside diversified peers such as Johnson & Johnson and Medtronic in higher-technology categories.AdvertisementHow this fits the Abbott Laboratories narrativeThe latest moves line up with the existing narrative that Abbott’s long term story is tied to a broad, multi segment healthcare portfolio and continued product development in diabetes and heart health. Adding Exact Sciences on top of its device pipeline would deepen that multi pronged model, which some analysts already view as a way to smooth earnings between more cyclical businesses like Nutrition and recurring, test based or device driven revenue streams.Risks and rewards investors should weigh⚠️ The Nutrition reset follows lost contracts, higher manufacturing costs and softer demand after price increases, which could keep pressure on margins if execution is slow. ⚠️ A US$21b acquisition brings integration risk and the possibility that expected synergies or cancer diagnostics growth do not fully materialize. 🎁 New diabetes and cardiovascular device la Read More